| 000 | 01781 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518015047.0 | ||
| 264 | 0 | _c20190503 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1528-0012 | ||
| 024 | 7 |
_a10.1053/j.gastro.2018.12.019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHvas, Christian Lodberg | |
| 245 | 0 | 0 |
_aFecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. _h[electronic resource] |
| 260 |
_bGastroenterology _cApr 2019 |
||
| 300 |
_a1324-1332.e3 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadverse effects |
| 650 | 0 | 4 |
_aClostridioides difficile _xdrug effects |
| 650 | 0 | 4 |
_aClostridium Infections _xdiagnosis |
| 650 | 0 | 4 | _aDenmark |
| 650 | 0 | 4 |
_aFecal Microbiota Transplantation _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFidaxomicin _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVancomycin _xadverse effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aDahl Jørgensen, Simon Mark | |
| 700 | 1 | _aJørgensen, Søren Peter | |
| 700 | 1 | _aStorgaard, Merete | |
| 700 | 1 | _aLemming, Lars | |
| 700 | 1 | _aHansen, Mette Mejlby | |
| 700 | 1 | _aErikstrup, Christian | |
| 700 | 1 | _aDahlerup, Jens Frederik | |
| 773 | 0 |
_tGastroenterology _gvol. 156 _gno. 5 _gp. 1324-1332.e3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1053/j.gastro.2018.12.019 _zAvailable from publisher's website |
| 999 |
_c29222448 _d29222448 |
||